Search

Library Entry

Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-se

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a case report on patients treated with immune-checkpoint blockade followed by targeted therapy, or vice versa, who experienced cutaneous toxicities with unique histological patterns, a feature that has not been well described in...

Library Entry

Advances in Cancer Immunotherapy™ Webinar Series - Updates from the Field: ESMO Congress Clinical Trials Recording

This webinar provided an update on developments in the field relating to content presented at the Advances in Cancer Immunotherapy programs and focused on applicable information for a clinical audience. More specifically, program organizers Theodore F. Logan, MD, and David F. McDermott, MD,...

Library Entry

Primer on Cancer Immunology and Immunotherapy

Primer on Cancer Immunology and Immunotherapy International Conference on Immunotherapy Radiotherapy Combinations September 20, 2018 Presentered by Gustave Roussy and SOCRATE, in collaboration with the Society for Immunotherapy of Cancer Program Summary Over 420 attendees from 4 continents,...

7 attachments

Library Entry

Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a short report of cases of biopsy proven acute tubulointerstitial nephritis (ATIN) and glomerulonephritis (GN) induced by CPIs and discuss potential mechanisms of these adverse effects. Authors: Omar Mamlouk , Umut Selamet , ...

Library Entry

Complete response of metastatic melanoma in a patient with Crohn’s disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a case report of a man with Crohn’s disease actively requiring immunosuppressive therapy who subsequently received pembrolizumab for metastatic melanoma. Authors: Christopher C. Frohne , Ernesto M. Llano , Ashley Perkovic , ...

Library Entry

Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a case report of a 68-year-old with metastatic melanoma, who developed transverse myelitis in the setting of immune checkpoint blockade and spinal irradiation for vertebral metastases. Authors: Victoria A. Chang , Daniel R....

Library Entry

Taking the bull by the horn: the frontline use of infliximab for the treatment of immune checkpoint inhibitor-induced enterocolitis

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a commentary that provides a narrative summary of their findings in light of the current clinical knowledge relevant to the understanding of immune-related enterocolitis. Author: Khashayar Esfahani JITC(2018) 6:154 #Article ...

Library Entry

A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a case report of a patient with stage IV pulmonary adenocarcinoma treated for 6 months with nivolumab who developed bilateral sterile conjunctivitis followed by oropharyngeal mucositis and esophagitis complicated by a severe...

Library Entry

High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a commentary on the evaluation of tumors based on both their immune phenotype and genomic mutation profile to determine which patients have a higher likelihood of responding to treatment with ICIs. Author: Saman Maleki Vareki ...

Library Entry

Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a case report about the first case of myocarditis in a patient with metastatic castration-resistant prostate cancer (mCRPC) treated with a combination of nivolumab, an anti-programmed cell death protein 1 antibody, and PROSTVAC, a...